TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer

SAN DIEGO, May 24, 2017 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration (AMD) and fibrotic diseases, announced today that the first patient has been dosed in a Phase 1/2 clinical trial of TRC253 in patients with metastatic castration-resistant prostate cancer (mCRPC).